Progression of a hepatosplenic gamma delta T-cell leukemia/lymphoma on hyperCVAD/MTX and ara-C: literature review and our institutional treatment approach by Saste, Abhijit et al.
Henry Ford Health System 
Henry Ford Health System Scholarly Commons 
Hematology Oncology Articles Hematology-Oncology 
1-1-2016 
Progression of a hepatosplenic gamma delta T-cell leukemia/
lymphoma on hyperCVAD/MTX and ara-C: literature review and 
our institutional treatment approach. 
Abhijit Saste 
Henry Ford Health System 
Javier Arias-Stella 
Henry Ford Health System 
Philip Kuriakose 
Henry Ford Health System, PKURIAK1@hfhs.org 
Follow this and additional works at: https://scholarlycommons.henryford.com/
hematologyoncology_articles 
Recommended Citation 
Saste A, Arias-Stella J, and Kuriakose P. Progression of a hepatosplenic gamma delta T-cell leukemia/
lymphoma on hyperCVAD/MTX and ara-C: literature review and our institutional treatment approach. Clin 
Case Rep 2016; 4(1):67-71. 
This Article is brought to you for free and open access by the Hematology-Oncology at Henry Ford Health System 
Scholarly Commons. It has been accepted for inclusion in Hematology Oncology Articles by an authorized 
administrator of Henry Ford Health System Scholarly Commons. 
CASE REPORT
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Key Clinical Message
A 24-year-old male presented with abdominal pain, fever, and palpable spleno-
megaly. His differential count revealed myelocytes, metamyelocytes, and nucle-
ated red cells. A bone marrow biopsy confirmed a diagnosis of hepatosplenic
gamma delta T-cell leukemia/lymphoma. We describe here our center’s diag-
nostic and treatment approach for this rare leukemia.
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Case Presentation
A 24-year-old male presented with 2 weeks of abdominal
pain, fever, weakness, and palpable splenomegaly. His
complete blood count showed a white cell count of
20,000/cmm, hemoglobin of 6.8 g/dL, and platelet count
of 42,000/cmm. His differential count revealed monocyto-
sis, myelocytes, metamyelocytes, and nucleated red cells.
His LDH was elevated at 1951 IU/L. Further testing
showed prolonged PT and PTT, low haptoglobin, and a
very high D-dimer suggesting disseminated intravascular
coagulation (DIC). Testing for mononucleosis, hepatitis,
and HIV were all negative. Cerebrospinal fluid (CSF) for
cytopathology and flow cytometry were normal. A bone
marrow biopsy was performed (Figs 1–6). A T-cell pre-
dominant infiltrate was noted with a sinusoidal pattern of
infiltration. The T cells were predominantly atypical T
cells, with a composite immunophenotype of CD3 and
CD45 being brightly positive, TIA1+, TCR cd+, CD4,
CD8+ (minority, dim), CD56+ (minority, dim), granzyme
B on flow cytometry. Testing for Epstein Barr Virus
(EBV) and terminal deoxynucleotidyl transferase (TdT)
were negative. This confirmed a diagnosis of
hepatosplenic gamma delta T-cell leukemia/lymphoma.
Computed tomography (CT) abdomen (Fig. 7) demon-
strated splenomegaly. Induction chemotherapy was initi-
Figure 1. Leishman stain of bone marrow aspirate smear shows an
intermediate sized cell with scant cytoplasm and blastoid nuclear
morphology with nuclear irregularities. These comprised
approximately 20% of aspirate smear cells.
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ated with hyperfractionated CVAD (cyclophosphamide,
vincristine, adriamycin, and dexamethasone)/(1A) alter-
nating with high-dose methotrexate (MTX) and cytara-
bine (ara-C)/(1B). Intrathecal cytarabine (IT ara-c)
prophylaxis was also started. A restaging bone marrow
biopsy after cycles 1A/1B showed residual disease. Hence
chemotherapy was changed to a second-line regimen
comprising ifosfamide, carboplatin, and etoposide (ICE).
He developed neurotoxicity from ifosfamide and sepsis
from pneumonia. His cytopenias continued to get worse
from disease progression requiring increasingly frequent
transfusion support. A restaging CT scan of the abdomen
after cycle 1 of ICE showed worsening splenomegaly.
Given poor cytoreduction of his leukemia with
chemotherapy, progressive multisystem organ dysfunction
and worsening performance status he was considered
transplant ineligible. He was eventually enrolled in hos-
pice about 6 months from the time of diagnosis.
Discussion
Etiopathogenesis of hepatosplenic gamma
delta T-cell leukemia/lymphomas
T cells in the thymus comprise two subtypes based on
their surface expression of either ab or cd T-cell receptors
(TCR) [1]. The TCR of ab T cells, which form the major-
ity, is encoded by alpha and beta genes, whereas the TCR
of cd T cell is encoded by the gamma and delta genes
[2]. cd T cells constitute only about 5% of lymphocyte
Figure 2. Hematoxylin and eosin stain of the clot section shows a
hypercellular marrow with some preservation of trilineage
hematopoiesis as well as a subtle, diffuse mononuclear infiltrate.
Figure 3. CD3 staining of bone marrow. Immunohistochemical stain
showing markedly increased T-cell infiltrate with sinusoidal and
interstitial pattern.
Figure 4. TIA-1 stain of bone marrow. Immunohistochemical stain
showing cells positive for TIA-1.
Figure 5. CD20 stain of bone marrow. Immunohistochemical stain
showing only scant B cells.
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population [3]. ab and cd type T cells originate from a
common multipotent double negative precursor in the
thymus that homes itself there after originating from the
bone marrow precursor lymphoid cells [4]. ab T cells
express CD4 or CD8 coreceptors [4]. ab T-cell activations
are restricted via MHC-directed antigen presentation.
cd T cells on the other hand do not express CD4/CD8
coreceptors, and do not require conventional antigen pre-
sentation through MHC expression for their activation
[4].
Hepatosplenic gamma delta T-cell leukemia/lymphoma
is a type of T-cell non-Hodgkin’s lymphoma that arises
from clonal expansion of cd T cells which have suffered a
derangement of their genetic machinery from unknown
reasons. It has been hypothesized that chronic MHC
unrestricted antigenic stimulation of cd T cells seen in
chronic infection/inflammation may be a causal factor
[5]. This is based on the fact that these occur with a
slightly higher incidence in immunosuppressed solid
organ transplant recipients and HIV patients where
Figure 6. Flow cytometry of bone marrow aspirate showing cytoplasmic CD3 and TCR cd positivity.
ª 2015 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. 69
A. Saste et al. Gamma delta T-cell leukemia/lymphoma:clinical approach
gamma delta T cells are overstimulated by varying anti-
genic challenges from repetitive infections [5, 6]. Associa-
tions with the use of infliximab, malaria, cytomegalovirus
(CMV), and EBV have been reported [6–9].
Epidemiology
It is a rare peripheral T-cell lymphoma [10]. Median age
at diagnosis is 34 years [11]. A slight male gender pre-
ponderance exists [11, 12].
Clinical features
All patients tend to have splenomegaly and bone marrow
involvement [11, 12]. In a case series of 21 patients, the
incidence of liver involvement was 67%, that of at least
one B symptom was 80%, and that of lymphadenopathy
was 13% [11].
This condition has a very aggressive clinical course. In
a study by Falchook et al., median duration of complete
remission (CR) was 8 months with CHOP like regimens.
Median overall survival (OS) was 11 months. Patients
who achieved a CR had a median OS of 13 months com-
pared with 7.5 months in patients who did not achieve a
CR [10].
Pathologic diagnostic correlates
This disease shows a distinct sinusoidal pattern of infil-
tration in the splenic red pulp with sparing of the
white pulp. The liver also shows classic sinusoidal infil-
tration with sparing of hepatic portal triads. Bone mar-
row morphology is often nonspecific, but is notable for
neoplastic cells in the sinusoids in early stages and an
interstitial pattern of infiltration in the later stages [10].
Atypical appearing lymphocytes and hemophagocytosis
may be noted. Immunophenotyping and TCR
rearrangement are necessary for diagnosis [12].
Immunohistochemistry (IHC) is classically CD3+,
TCRd1+, TIA-1+, CD4, and CD8. TCR rearrange-
ment shows a clonal rearrangement of the cd gene of
the T cell – a hallmark of this disease [10, 12]. Few
cases have also shown rearrangement of the ab gene
[10]. Isochromosome 7q has shown a higher prevalence
in this condition [10].
Our institutional treatment approach
After a diagnosis, which is usually made on a bone mar-
row biopsy and aspiration, we conduct a staging work up
that comprises CT scan of the chest, abdomen, and pelvis
looking specifically for lymphadenopathy and hep-
atosplenomegaly. We perform a MRI brain only if symp-
toms suggest neurologic involvement. A lumbar puncture
(LP) is carried out in all patients for performing a cere-
brospinal fluid (CSF) flow cytometry and cytopathology
for involvement of the nervous system. One prophylactic
dose of intrathecal ara-c is administered at the conclusion
of this first LP.
All of our cases undergo a multidisciplinary review at a
leukemia tumor board meeting prior to initiating treat-
ment. Our standard first-line therapy is HyperCVAD
alternated with MTX and high-dose cytarabine (ara-c)
along with intrathecal prophylaxis, to achieve cytoreduc-
tion followed by consolidation with allogeneic bone mar-
row transplant (allo-SCT), if eligible. We assess response
with a restaging marrow after completing the first cycle of
HyperCVAD to help arrive at a decision about continuing
the same chemotherapy regimen versus switching to an
alternative regimen.
If HyperCVAD is not possible given a poor perfor-
mance status of the patient, we use a clinical trial as our
standard second-line approach, if one is available.
In the absence of a clinical trial, we approach our
patients based on their clinical status.
 If clinical status is relatively well maintained, then a
combination regimen such as ICE/DHAP/ESHAP is
employed.
 If clinical status is not favorable, then a single agent
approach, such as with romidepsin or pentostatin is
considered, unless a poor performance status dictates
eligibility for supportive care alone.
Figure 7. CT scan of the abdomen showing massive splenomegaly.
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Although alemtuzumab may be employed as a single
agent, it may not be tolerated by patients with a poor
performance status.
During their chemotherapy treatments, we offer our
patients supportive treatment with prophylactic antibi-
otics, antivirals, and antifungals, judicious transfusion
support, and prophylaxis against tumor lysis syndrome.
We routinely involve specialized chemopharmacists and
chemonurses to be a part of our support team for the
preparation, dosing, and monitoring of chemotherapy.
We also involve an appropriate palliative pain service and




1. Bruno, L., A. Scheffold, A. Radbruch, and M. J. Owen.
1999. Threshold of pre-T-cell-receptor surface expression is
associated with ab T-cell lineage commitment. Curr. Biol.
3:559–568.
2. Yan-Ling, W., Y.-P. Ding, Y. Tanaka, L.-W. Shen, C.-H.
Wei, N. Minato, et al. 2014. cd T Cells and Their Potential
for Immunotherapy. Int. J. Biol. Sci. 10:119–135.
3. Roden, A. C., W. G. Morice, and C. A. Hanson.
Immunophenotypic attributes of benign peripheral blood
cd T cells and conditions associated with their increase.
Arch. Pathol. Lab. Med. 2008. 132:1774–1780.
4. Kreslavsky, T., M. Gleimer, A. I Garbe, and H. von
Boehmer. ab versus cd fate choice: counting the T-cell
lineages at the branch point. Immunol. Rev. 2010.
238:169–181.
5. Poccia, F., M. Wallace, V. Colizzi, and M. Malkovsky.
1998. Possible protective and pathogenic roles of gamma
delta T lymphocytes in HIV-infections (Review). Int. J.
Mol. Med. 1:409–413.
6. Couzi, L., X. Lafarge, V. Pitard, M. Neau-Cransac, C.
Dromer, M. A. Billes, et al. 2011. Gamma-delta T cell
expansion is closely associated with cytomegalovirus
infection in all solid organ transplant recipients. Transpl.
Int. 24:e40–e42.
7. Tsunematsu, S., M. Natsuizaka, H. Fujita, N. Otsuka, K.
Terashita, F. Sato, et al. 2014. Hepatosplenic gamma-delta
T-cell lymphoma associated with Epstein-Barr virus.
Intern. Med. 53:2079–2082.
8. Hassan, R., S. A. Franco, C. G. Stefanoff, S. O. Romano,
H. R. Diamond, L. G. Franco, et al. 2006. Hepatosplenic
gammadelta T-cell lymphoma following seven malaria
infections. Pathol. Int. 56:668–673.
9. Kelsen, J., A. Dige, H. Schwindt, F. D’Amore, F. S.
Pedersen, J. Agnholt, et al. 2011. Infliximab induces clonal
expansion of cd-T cells in Crohn’s disease: a predictor of
lymphoma risk? PLoS One 6:e17890.
10. Falchook, G. S., F. Vega, N. H. Dang, F. Samaniego, M. A.
Rodriguez, R. E. Champlin, et al. 2009. Hepatosplenic
gamma-delta T-cell lymphoma: clinicopathological features
and treatment. Ann. Oncol. 20:1080–1085.
11. Belhadj, K., F. Reyes, J. P. Farcet, H. Tilly, C. Bastard, R.
Angonin, et al. 2003. Hepatosplenic gammadelta T-cell
lymphoma is a rare clinicopathologic entity with poor
outcome: report on a series of 21 patients. Blood
102:4261–4269.
12. Wang, F. X., X. J. Zhang, and Z. R. Dong. 2005. A case of
hepatosplenic gammadelta T cell lymphoma. Zhongguo
Shi Yan Xue Ye Xue Za Zhi 13:505–508.
ª 2015 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. 71
A. Saste et al. Gamma delta T-cell leukemia/lymphoma:clinical approach
